At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study of Ramucirumab for Advanced, Pre-Treated Biliary Cancers
In Brief
A Phase 2 clinical trial evaluating Laboratory Biomarker Analysis and Ramucirumab for Cholangiocarcinoma and 11 related conditions. Completed, enrolled 61 participants across 1 site.
Detailed Summary
This phase II trial studies how well ramucirumab works in treating patients with previously treated biliary cancers that have spread to other places in the body and usually cannot be cured or controlled with treatment (advanced) or have spread to other places in the body (metastatic) and cannot be removed by surgery. Immunotherapy with monoclonal antibodies, such as ramucirumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Study Details
Timeline
Interventions
Correlative studies
Given IV